ShareThis Page
World

GOP congressman from New York charged with insider trading

| Wednesday, Aug. 8, 2018, 11:06 a.m.
Republican U.S. Rep. Christopher Collins of western New York state has been indicted on charges that he used inside information about a biotechnology company to make illicit stock trades.
Republican U.S. Rep. Christopher Collins of western New York state has been indicted on charges that he used inside information about a biotechnology company to make illicit stock trades.

NEW YORK — Republican U.S. Rep. Christopher Collins of western New York state has been indicted on charges that he used inside information about a biotechnology company to make illicit stock trades.

The charges were announced and the indictment unsealed in New York City on Wednesday.

The indictment charges Collins, the congressman’s son and the father of the son’s fiance, with conspiracy, wire fraud and other counts.

Prosecutors said the charges relate to a scheme to gain insider information about Innate Immunotherapeutics Limited, a biotechnology company headquartered in Sydney, Australia, with offices in Auckland, New Zealand.

According to the indictment, Collins, 68, got early word that a drug the company developed to treat multiple sclerosis wasn’t performing well in a medical trial and passed on the tip to his son, Cameron.

Collins, whose district covers parts of western New York between Buffalo and Rochester, has denied any wrongdoing. When the House Ethics Committee began investigating the stock trades a year ago, his spokeswoman called it a “partisan witch hunt.”

“We will answer the charges filed against Congressman Collins in court and will mount a vigorous defense to clear his good name,” his attorneys, Jonathan Barr and Jonathan New, said in a statement Wednesday. “It is notable that even the government does not allege that Congressman Collins traded a single share of Innate Therapeutics stock. We are confident he will be completely vindicated and exonerated.”

All three defendants were in federal custody Wednesday and were expected to make their initial court appearance in the afternoon.

Collins was a member of Innate’s board of directors and held nearly 17 percent of the stock. When the drug trials failed, the public announcement caused the stock price of Innate to plunge 92 percent.

Prosecutors allege that Collins passed along secrets to his son in June 2017. They say Cameron Collins traded on the inside information and passed it to a third defendant, Stephen Zarsky. They say Zarsky traded on it and tipped off at least three others.

Prosecutors say the three avoided over $768,000 in losses by trading ahead of the public announcement of the failed drug trials.

The advocacy group Public Citizen filed a request for an investigation of Collins’ stock dealings with the Office of Congressional Ethics and the Securities and Exchange Commission in January of 2017.

Several other members of Congress have come under scrutiny for purchasing shares of Innate Immunotherapeutics, including then-Rep. Tom Price, R-Ga. Price went on to become President Donald Trump’s first secretary of the Health and Human Services Department.

Democrats made an issue of Price’s purchase at his Senate confirmation hearings in early 2017, after the Wall Street Journal reported that company officials said Price was allowed to buy the stocks at a low price.

Price, who bought about 400,000 shares of the stock, said he’d learned of the firm through Collins but testified that the price he received was available to any investor.

Price resigned as health secretary under criticism for taking pricey charter flights at taxpayers’ expense.

Collins was first elected to Congress in 2012. He faces re-election this fall.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me